GLENMARK

GLENMARK PHARMACEUTICALS

Mid Cap BSE: 532296 NSE: GLENMARK
₹431.25
9.4 (2.23%)
  • Advice
  • Hold
As on 08 December, 2022 | 18:18

Glenmark Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in GLENMARK PHARMACEUTICALS

Start SIP

Glenmark Pharmaceuticals Share Price

Glenmark Pharmaceuticals Share Returns

  • Over 1 Month 1.95%
  • Over 3 Month 12.5%
  • Over 6 Month 9.07%
  • Over 1 Year -15.06%

Glenmark Pharmaceuticals Key Statistics

P/E Ratio 14.7
PEG Ratio -0.7
Market Cap Cr 12,169
Price to Book Ratio 1.3
EPS 58.3
Dividend 0.6
Relative Strength Index 56.25
Money Flow Index 64.11
MACD Signal 6.39
Average True Range 11.61

Glenmark Pharmaceuticals Investment Rating

  • Master Rating:
  • Glenmark Pharms. (Nse) has an operating revenue of Rs. 12,345.10 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 12% is healthy, ROE of 10% is good. The company has a reasonable debt to equity of 28%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around 3% and 3% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 109 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Glenmark Pharmaceuticals Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 2,1531,8721,7212,0072,1812,1291,823
Operating Expenses Qtr Cr 1,8261,4781,6241,5231,7211,5851,494
Operating Profit Qtr Cr 382434162510460557356
Depreciation Qtr Cr 46454241403737
Interest Qtr Cr 52407450535963
Tax Qtr Cr 177203198812310932
Net Profit Qtr Cr 423493206549754489342

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
431.25
9.4 (2.23%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 425.32
  • 50 Day
  • 413.92
  • 100 Day
  • 407.6
  • 200 Day
  • 419.66
  • 20 Day
  • 426.73
  • 50 Day
  • 410.78
  • 100 Day
  • 395.59
  • 200 Day
  • 408.09

Glenmark Pharmaceuticals Resistance and Support

PIVOT
₹423.25
Resistance
First Resistance 426.3
Second Resistance 430.75
Third Resistance 433.8
RSI 56.25
MFI 64.11
MACD Single Line 6.39
MACD 5.3
Support
First Resistance 418.8
Second Resistance 415.75
Third Resistance 411.3

Glenmark Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 608,395 25,236,225 41.48
Week 737,803 26,221,504 35.54
1 Month 1,191,977 31,933,077 26.79
6 Month 1,103,672 33,993,088 30.8

Glenmark Pharmaceuticals Result Highlights

Glenmark Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8141.58 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2022. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.
Market Cap 12,161
Sales 7,939
Shares in Float 14.95
No of funds 278
Yield 0.59
Book Value 0.71
U/D Vol ratio 2.1
LTDebt / Equity 15
Alpha -0.08
Beta 0.97

Glenmark Pharmaceuticals

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 46.65%46.65%46.65%
Mutual Funds 6.26%5.81%6.18%
Insurance Companies 4.16%
Foreign Portfolio Investors 23.14%24.23%24.12%
Financial Institutions/ Banks 0.22%0.2%0.44%
Individual Investors 16.47%16.32%15.88%
Others 3.1%6.79%6.73%

Glenmark Pharmaceuticals Management

Name Designation
Mr. Glenn Saldanha Chairman & Managing Director
Mrs. Cherylann Pinto Executive Director - Corporate Affairs
Mr. V S Mani Executive Director & Global CFO
Mr. Rajesh V Desai Non Executive Director
Dr. Brian W Tempest Non Executive Director
Mr. Dipankar Bhattacharjee Non Executive Director
Mr. Bernard Munos Non Executive Director
Mr. Sridhar Gorthi Non Executive Director
Mrs. B E Saldanha Non Executive Director
Mr. D R Mehta Non Executive Director
Ms. Saira Ramasastry Non Executive Director

Glenmark Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Glenmark Pharmaceuticals Corporate Action

Date Purpose Remarks
2022-11-11 Quarterly Results
2022-08-10 Quarterly Results
2022-05-27 Audited Results & Final Dividend
2022-02-11 Quarterly Results
2021-11-12 Quarterly Results

Glenmark Pharmaceuticals MF Shareholding

Name Amount(cr)
HDFC Mid-Cap Opportunities Fund Growth 35120
Kotak Equity Arbitrage Fund Growth 22082
Aditya Birla Sun Life Flexi Cap Fund Growth 16422
Kotak Balanced Advantage Fund Regular Growth 14553
ICICI Prudential Equity Arbitrage Fund Regular Growth 10891

Glenmark Pharmaceuticals FAQs

What is Share Price of Glenmark Pharmaceuticals ?

Glenmark Pharmaceuticals share price is ₹431 As on 08 December, 2022 | 18:04

What is the Market Cap of Glenmark Pharmaceuticals ?

The Market Cap of Glenmark Pharmaceuticals is ₹12168.5 Cr As on 08 December, 2022 | 18:04

What is the P/E ratio of Glenmark Pharmaceuticals ?

The P/E ratio of Glenmark Pharmaceuticals is 14.7 As on 08 December, 2022 | 18:04

What is the PB ratio of Glenmark Pharmaceuticals ?

The PB ratio of Glenmark Pharmaceuticals is 1.3 As on 08 December, 2022 | 18:04

Q2FY23